Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome
Status:
Not yet recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
The objectives of this clinical trial are to evaluate the safety and tolerability of
topically applied ATR12-351, to understand what the body does to ATR12-351, and to observe
treatment benefits of the drug in approximately 12 adult patients with Netherton Syndrome
(NS). ATR12-351 will be applied to skin lesions on one side of the body, while the vehicle
control will be applied to similar lesion on the other side of the body twice daily for 2
weeks.